Abstract (250 words)

Background and aims:
Hepatitis delta virus (HDV) infection accelerates the progression of hepatitis B virus (HBV)-related liver disease. We assessed the epidemiological characteristics of HDV infection in the nationwide Swiss HIV Cohort Study and evaluated its impact on clinical outcomes.
Methods:
All HIV-infected patients with a positive HBsAg test were considered and tested for anti-HDV antibodies. HDV amplification and sequencing were performed in anti-HDV-positive patients.
Demographic and clinical characteristics at initiation of antiretroviral therapy, as well as causes of death were compared between HDV-positive and HDV-negative individuals using descriptive statistics. Kaplan-Meier and multivariable Cox regression analyses were used to evaluate the association between HDV infection and overall mortality, liver-related mortality as well as incidence of hepatocellular carcinoma (HCC).
Results:
Of 818 patients with a positive HBsAg, 771 (94%) had a stored serum sample available and were included. The prevalence of HDV infection was 15.4% (119/771, 95% confidence interval (CI): 12.9-18.0) and the proportion of HDV-positive patients with HDV replication 62.9% (73/116). HDV-infected patients were more likely to be persons who inject drugs (PWID) (60.6% vs. 9.1%) and to have a positive HCV serology (73.1% vs. 17.8%) compared to HDV-uninfected ones. HDV infection was strongly associated with overall death (adjusted hazard ratio 2.33, 95% CI 1.41-3.84), liver-related death (7.71, 3.13-18.97 ) and with the occurrence of HCC (9.30, 3.03-28.61). Results were similar when PWID or HCVcoinfected patients were excluded from the analyses.
Conclusions:
The prevalence of HDV in HBsAg-positive patients in the SHCS is high and HDV infection is independently associated with mortality and liver-related events, including HCC. HDV accelerates the course of HBV-related liver disease, including the progression to liver cirrhosis, hepatic decompensation and possibly hepatocellular carcinoma (HCC) 7, 8 . In HIVinfected patients, the presence of HDV-coinfection has been associated with a higher incidence of hepatic flares and decompensation as well as an increased mortality 9, 10 . However, most studies assessing the impact of HDV on long-term outcomes in HIV/HBVcoinfected individuals were limited by small sample sizes, highly selected study populations, . Thus, it's impact on mortality and liver-related complications needs to be evaluated in prospective studies with long-term follow-up.
In this study, we aimed to describe the main epidemiological characteristics of HDV infection and to evaluate its impact on clinical outcomes in the Swiss HIV Cohort Study (SHCS) 13 .The systematic ascertainment of death causes and liver-related complications in the SHCS allowed us to perform a detailed assessment of liver-related outcomes in a nationwide representative cohort of HIV/HBV-coinfected individuals.
Patients and methods
Swiss HIV Cohort Study (SHCS):
The SHCS (www.shcs.ch) is a prospective cohort study with ongoing enrollment of HIVinfected adults in Switzerland since 1988 13 . 
Laboratory analyses:
The ETI-AB-DELTA-2 TM (Diasorin, Saluggia, Italy), a competition ELISA test, was used to We performed several sensitivity analyses. We repeated the main analysis comparing HIV/HBV/HDV-RNA negative and HIV/HBV/HDV-RNA positive patients. We evaluated the association between HDV infection and the main outcomes after the exclusion of persons who inject drugs (PWID) and patients with a positive HCV serology. As these two categories of patients are more likely to have multiple comorbidities and to die during follow-up, their over-representation in the HDV-positive group could have had an important impact on our results. As longitudinal data on HBV replication were lacking, we used TDF treatment as a proxy for HBV suppression, and evaluated the association between HDV infection and the main outcomes after the exclusion of persons who had never been treated with TDF. All statistical analyses were performed using Stata Version 13. 
Characteristics of HDV infection
Fifteen (12.6%) patients from the HDV-positive group and 29 (4.5%) from the HDV-negative group never started ART during follow-up and were excluded from the longitudinal analyses. Fig. 3A) . The cumulative probability of liver-related deaths as well as HCC were significantly higher in HDV-positive patients compared to HDV-negative ones (both p<0.001; Fig. 3B and 3C) .
In multivariable analyses, HDV infection was strongly associated with overall death (adjusted hazard ratio [aHR] 2.33, 95% CI 1.41-3.84) ), with liver-related mortality (aHR 7.71, 95% CI 3.13-18.97), and with the occurrence of HCC (aHR 9.30, 95% CI 3.03-28.61, Fig. 4 and Table S1 ). The risk for non-liver related deaths did not differ significantly between HDVpositive and -negative patients (aHR 1.36, 95% CI 0.72-2.57). In analyses comparing HDV-RNA-negative and HDV-RNA-positive patients, we found that the cumulative probability for overall death, liver-related death and HCC were significantly higher in HDV-RNA-positive patients ( Table S2, Fig. 3 , panels D-F). In multivariable analyses, HDV replication was strongly associated with overall death (adjusted hazard ratio [aHR] 7.14, 95% CI 1.60-31.85), liver-related mortality and the occurrence of HCC. There were no liver-related deaths and no HCC in patients that were HDV-RNA-negative. Results were similar when PWID or HCVinfected individuals were excluded from the analyses (Fig. 4) . In analyses stratified by viral hepatitis coinfection sub-group (HIV/HBV, HIV/HBV/HDV, HIV/HBV/HCV and HIV/HBV/HDV/HCV), overall survival was lowest in the two groups of HDV-infected individuals, independently of anti-HCV antibody status or replicating HCV infection ( Fig. S2 and S3). In analyses restricted to patients who had received TDF (77%), the point estimate of the association between HDV infection and overall death remained similar (aHR 2.03, 95%
CI 0.80-5.15).
Discussion:
The prevalence of HDV infection was high among HIV/HBV-coinfected individuals in Switzerland: 15% were antibody-positive and 63% of them had detectable viral replication.
Over nine years of individual follow-up on ART, HDV-infected patients were twice as likely to die as HDV-uninfected ones. The excess mortality in HDV-positive patients was driven by liver related deaths: HDV-positive individuals were eight times more likely to die from liver disease and nine times more likely to develop an HCC compared to HDV-negative patients.
These associations were robust, remaining similar in all sensitivity analyses.
The prevalence of HDV infection in our cohort was similar to the findings from the EuroSIDA collaboration but slightly higher than the estimate reported in cohort studies from France and North America 17, 18 . As false-positive HDV screening results seem to be frequent in the setting of HIV-infection 19 , we performed a confirmatory serology in all patients with a negative HDV RNA in order to strengthen our HDV prevalence estimate. In our study, 14% of positive HDV screening tests were false-positive. After the exclusion of these patients, 63% of HDVpositive patients had a detectable HDV viral load, which was lower than the proportion found in the EuroSIDA study 4 . Although the main reason for this difference remains unclear, the unselected nature of our study population, in which all patients were screened for HBV and . Injection drug use being the most probable route of HDV transmission for the majority of patients included in our study, HCV infection was also present in many of them. The complex interplay between HBV, HCV and HDV has been described in several previous reports which generally showed HDV to be the dominant virus, often leading to the suppression of HBV as well as HCV 17, 22, 23 . . In our study the hazard of death, liver-related death and HCC was mainly driven by HDV-RNA-positive patients.
However, due to the low number of HDV-infected patients included in previous studies of HIV-positive individuals, data on the impact of HDV replication on liver-related outcomes and mortality are scarce.
HCC was diagnosed in 23 patients of which 20 died during the study period. HDV-positive individuals were 9 times more likely to develop HCC as compared to HDV-uninfected HBV positive persons. Chronic HBV infection is the single most important risk factor of HCC worldwide [24] [25] [26] , and this risk has been shown to correlate with HBV replication 27 . However, the impact of HDV on liver carcinogenesis and its contribution to global HCC epidemiology remains unclear. In cirrhotic HBV-infected patients, Fattovich et al. found a 3-fold increase in HCC incidence among HDV-infected patients, whereas similar rates of HCC were found in HBV-and HBV/HDV-infected patients in a retrospective study from London. 20, 28 . In Italy, Hepatitis delta virus (HDV) infection accelerates the progression of hepatitis B virus (HBV)-related liver disease. In a nationwide cohort of HIV-infected individuals in Switzerland, 15% of HBV-coinfected patients had antibodies to HDV infection, of which a majority had active HDV replication. HDV-infected individuals were 2.5 times more likely to die, 8 times more likely to die from a liver-related cause and 9 times more likely to develop liver cancer compared to HDV-uninfected ones. Our results emphasize the need for prevention programs (including HBV vaccination), the systematic screening of at risk populations as well as close monitoring, and underline the importance of developing new treatments for chronic HDV infection. 
